<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179010</url>
  </required_header>
  <id_info>
    <org_study_id>030371</org_study_id>
    <nct_id>NCT00179010</nct_id>
  </id_info>
  <brief_title>AMP as a Better Delivery System of Adenosine</brief_title>
  <official_title>Use of AMP to Improve Tissue Delivery of Adenosine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adenosine and AMP are substances normally present in the body. Adenosine is also given for
      the treatment of some heart rhythm problems and may be used to reduce heart damage during
      heart attacks. The problem in using adenosine is that it is taken up by cells and, therefore,
      very little of the adenosine we give by vein or in the artery actually reaches the tissue. We
      propose to use AMP as a way to improve delivery of adenosine. AMP is inactive by itself, but
      is converted to adenosine in tissue. We hope that by giving AMP we will increase levels of
      adenosine in tissue. To see if this is true, we will give either adenosine or AMP into the
      forearm artery while we measure how much adenosine reaches the forearm tissue.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated because funding could not be secured
  </why_stopped>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial Adenosine Levels</measure>
    <time_frame>Microdyalysis samples for adenosine, were collected for 15 minutes at each stage of the study (baseline and each dose of adenosine or AMP)</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Forearm Blood Flow</measure>
    <time_frame>End of each stage (minute 15) of the study (baseline and each dose of adenosine or AMP ia infusions)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>Adenosine then Adenosine Mono Phosphate (AMP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrarterial infusion of adenosine then same subject switch to AMP one month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adenosine Mono Phosphate (AMP) then adenosine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrarterial infusion of AMP then same subject switch to Adenosine one month apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each</description>
    <arm_group_label>Adenosine Mono Phosphate (AMP) then adenosine</arm_group_label>
    <arm_group_label>Adenosine then Adenosine Mono Phosphate (AMP)</arm_group_label>
    <other_name>Ado</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine Mono Phosphate (AMP)</intervention_name>
    <description>Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)</description>
    <arm_group_label>Adenosine Mono Phosphate (AMP) then adenosine</arm_group_label>
    <arm_group_label>Adenosine then Adenosine Mono Phosphate (AMP)</arm_group_label>
    <other_name>AMP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Age 18-65

          -  Non smokers

        Exclusion Criteria:

          -  Smokers

          -  Any chronic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Italo Biaggioni, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>July 13, 2015</results_first_submitted>
  <results_first_submitted_qc>May 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Italo Biaggioni</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Adenosine</keyword>
  <keyword>AMP</keyword>
  <keyword>Microdialysis</keyword>
  <keyword>Blood Flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited through mass e-mails and flyers posted in campus</recruitment_details>
      <pre_assignment_details>Subjects were randomly assigned to each treatment arm, after being screened for any medical problem that would be considered a contraindication for the study according to the physician performing the initial evaluation. Once subjects completed one arm, they were crossed to the other arm and studied at lest one month after.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adenosine First Then AMP</title>
          <description>Intrarterial infusion of adenosine first
Adenosine: Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
Subjects in this group were assigned to received intrarterial infusions of adenosine and then crossed to the other arm (AMP) after at least 1 month.</description>
        </group>
        <group group_id="P2">
          <title>Adenosine Mono Phosphate (AMP) First Then Adenosine</title>
          <description>Intrarterial infusion of AMP first
Adenosine Mono Phosphate (AMP): Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
Subjects intros group were assigned to received intrarterial infusions of AMP and then crossed to the other arm (adenosine), at least 1 month after.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Muscle probe defective</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to place arterial line</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adenosine Mono Phosphate (AMP) First</title>
          <description>Intrarterial infusion of AMP
Adenosine Mono Phosphate (AMP): Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)</description>
        </group>
        <group group_id="B2">
          <title>Adenosine First</title>
          <description>Intrarterial infusion of adenosine
Adenosine: Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="10"/>
                    <measurement group_id="B2" value="37" spread="10"/>
                    <measurement group_id="B3" value="37" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Interstitial Adenosine Levels</title>
        <time_frame>Microdyalysis samples for adenosine, were collected for 15 minutes at each stage of the study (baseline and each dose of adenosine or AMP)</time_frame>
        <population>13 subjects received both treatments. 3 subject did not complete the study and were excluded. We are reporting data in only 10 subjects that have collected samples.</population>
        <group_list>
          <group group_id="O1">
            <title>Adenosine</title>
            <description>Intrarterial infusion of adenosine
Adenosine: Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each</description>
          </group>
          <group group_id="O2">
            <title>Adenosine Mono Phosphate (AMP)</title>
            <description>Intra-arterial infusion of AMP</description>
          </group>
        </group_list>
        <measure>
          <title>Interstitial Adenosine Levels</title>
          <population>13 subjects received both treatments. 3 subject did not complete the study and were excluded. We are reporting data in only 10 subjects that have collected samples.</population>
          <units>nM</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Third dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" spread="15.7"/>
                    <measurement group_id="O2" value="91.7" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" spread="12.7"/>
                    <measurement group_id="O2" value="91.1" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" spread="18.6"/>
                    <measurement group_id="O2" value="86.2" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.854</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forearm Blood Flow</title>
        <time_frame>End of each stage (minute 15) of the study (baseline and each dose of adenosine or AMP ia infusions)</time_frame>
        <population>This was an exploratory Outcome and was abandoned.</population>
        <group_list>
          <group group_id="O1">
            <title>Adenosine</title>
            <description>Intrarterial infusion of adenosine
Adenosine: Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each</description>
          </group>
          <group group_id="O2">
            <title>Adenosine Mono Phosphate (AMP)</title>
            <description>Intrarterial infusion of AMP
Adenosine Mono Phosphate (AMP): Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)</description>
          </group>
        </group_list>
        <measure>
          <title>Forearm Blood Flow</title>
          <population>This was an exploratory Outcome and was abandoned.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adenosine</title>
          <description>Intrarterial infusion of adenosine
Adenosine: Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each</description>
        </group>
        <group group_id="E2">
          <title>Adenosine Mono Phosphate (AMP)</title>
          <description>Intrarterial infusion of AMP
Adenosine Mono Phosphate (AMP): Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Italo Biaggioni, MD., Professor of Medicine and Pharmacology</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>(615) 936-3420</phone>
      <email>italo.biaggioni@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

